NZ319891A - Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation - Google Patents

Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation

Info

Publication number
NZ319891A
NZ319891A NZ319891A NZ31989196A NZ319891A NZ 319891 A NZ319891 A NZ 319891A NZ 319891 A NZ319891 A NZ 319891A NZ 31989196 A NZ31989196 A NZ 31989196A NZ 319891 A NZ319891 A NZ 319891A
Authority
NZ
New Zealand
Prior art keywords
tumour
cytotoxic
stimulation
virus
lymphocyte response
Prior art date
Application number
NZ319891A
Other languages
English (en)
Inventor
Louis D Falo Jr
Kenneth L Rock
Original Assignee
Univ Pittsburgh
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, Dana Farber Cancer Inst Inc filed Critical Univ Pittsburgh
Publication of NZ319891A publication Critical patent/NZ319891A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ319891A 1995-09-28 1996-09-27 Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation NZ319891A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53555695A 1995-09-28 1995-09-28
PCT/US1996/015728 WO1997011605A1 (en) 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Publications (1)

Publication Number Publication Date
NZ319891A true NZ319891A (en) 1999-01-28

Family

ID=24134735

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ319891A NZ319891A (en) 1995-09-28 1996-09-27 Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation

Country Status (15)

Country Link
EP (1) EP0863704A4 (hu)
JP (1) JPH11512724A (hu)
KR (1) KR19990063672A (hu)
CN (1) CN1201369A (hu)
AU (1) AU716497B2 (hu)
BG (1) BG102355A (hu)
CA (1) CA2233278A1 (hu)
CZ (1) CZ92998A3 (hu)
HU (1) HUP9802651A3 (hu)
NO (1) NO981386L (hu)
NZ (1) NZ319891A (hu)
PL (1) PL325953A1 (hu)
SK (1) SK40198A3 (hu)
TR (1) TR199800573T2 (hu)
WO (1) WO1997011605A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044446A1 (en) * 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
JP2002507392A (ja) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 遺伝子ワクチンの免疫調節特性の最適化
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
JP2002542264A (ja) * 1999-04-21 2002-12-10 パウダージェクト ヴァクシンズ，インコーポレイテッド 核酸による免疫化
JP4430868B2 (ja) * 2001-03-30 2010-03-10 ジーエイチシー リサーチ ディベロップメント コーポレイション 単球に特異的な粒子性送達媒体
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US11529414B2 (en) 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Also Published As

Publication number Publication date
HUP9802651A2 (hu) 1999-02-01
HUP9802651A3 (en) 2001-08-28
SK40198A3 (en) 1998-11-04
EP0863704A4 (en) 2003-09-10
JPH11512724A (ja) 1999-11-02
CA2233278A1 (en) 1997-04-03
EP0863704A1 (en) 1998-09-16
NO981386L (no) 1998-05-28
WO1997011605A1 (en) 1997-04-03
NO981386D0 (no) 1998-03-26
KR19990063672A (ko) 1999-07-26
CN1201369A (zh) 1998-12-09
TR199800573T2 (xx) 1998-07-21
CZ92998A3 (cs) 1998-09-16
AU716497B2 (en) 2000-02-24
PL325953A1 (en) 1998-08-17
BG102355A (en) 1999-04-30
AU7251596A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
MW390A1 (en) Antiviral or antibacterial compound and method of use
FI883501A (fi) Menetelmä akryylipolymeerigeelin jatkuvaksi valmistamiseksi
DE69600595D1 (de) Zweikammer-herzschrittmacher-system mit optimierter verstellung der av-verzögerung zur behandlung von kardiomyopathien
DE69632321D1 (de) Schrittmachersystem zur verringerung des defilibrationsschwellenwertes
ZA913036B (en) Pharmaceutical compositions comprising tnf for induction of nerve regeneration
NZ319891A (en) Stimulation of cytotoxic t lymphocyte response to tumour or virus by targeted particulate polynucleotide genetic immunisation
DE69637523D1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
IT1155059B (it) Procedimento per il trattamento di prodotti finali provenienti dalla desolforazione di gas di combustione
WO1999024077A3 (en) Compositions and methods for targeted delivery of biologically-active factors
AU628288B2 (en) Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
PL330415A1 (en) Genes increasing immunity of plants to diseases
PL271284A1 (en) Method effectuating algae cultures of increased biological effectiveness
EP0372523A3 (en) Process of preparing alpha-amylase inhibiting substances from wheat
DE19681439T1 (de) Modifizierung von Polypeptidarzneimitteln zur Erhöhung des Elektrotransportflusses
AU4647993A (en) Method of stimulating the immune system
IT8720564A0 (it) Impianto elettrostatico per il trattamento di prodotti alimentari.
GB8820803D0 (en) Dna clone of human type iv collagenase
HUP9903854A3 (en) Process for the purification of recombinant human interleukin-8
HU9301581D0 (en) Recombinant insect virus having reduced transfer capability from one host organism to another and method for producing it
HU9802142D0 (en) Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system
EP0584339A4 (en) Method of delivering therapeutic substances to the brain
AU9626498A (en) Dipeptides for the treatment of diseases related to the biological effect of endothelin
MY106984A (en) Antiviral or antibacterial composition and method of use.
GB9621703D0 (en) Composition for the treatment of conditions caused by herpes virus
ITBO950040A0 (it) Sistema innovativo per fabbricare manufatti ceramici elettrotermici